---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-25-000090"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:25:34.284283+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q3 net sales $804.6M (+7.7%), adjusted EPS $1.96; raises FY guidance

## Summary
- Proprietary Products HVP Components net sales $390M, +16.3% YoY, driven by GLP-1 products and HVP conversion.
- Full-year 2025 net sales guidance raised to $3.060-3.070B; adjusted EPS guidance raised to $7.06-7.11.
- Q4 2025 guidance: net sales $790-800M, adjusted diluted EPS $1.81-1.86.
- Free cash flow nine months $293.9M, +53.7% YoY; repurchased 552,593 shares for $134.0M.

## SEC filing metadata
- accession: 0000105770-25-000090
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/0000105770-25-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/wst-20251023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-25-000090
- JSON: https://secwatch.observer/filing/0000105770-25-000090.json
- Plain text: https://secwatch.observer/filing/0000105770-25-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.